Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-01-11T05:55:46.775Z Has data issue: false hasContentIssue false

Chapter 5 - Disorders of the Hypothalamic–Pituitary–Adrenal Axis

Cushing’s Syndrome and Beyond

Published online by Cambridge University Press:  14 October 2021

By
Aoife M. Egan  and
Anne M. Doherty
Edited by
Anne M. Doherty ,
Aoife M. Egan  and
Sean Dinneen
Anne M. Doherty
Affiliation:
University College Dublin
Aoife M. Egan
Affiliation:
Division of Endocrinology and Metabolism, Mayo Clinic, Minnesota, USA
Sean Dinneen
Affiliation:
School of Medicine, National University of Ireland, Galway
Get access

Summary

The primary endocrine effectors of the stress response are located in the paraventricular nucleus of the hypothalamus, the anterior lobe of the pituitary gland and the adrenal gland. These structures are referred to as the hypothalamic–pituitary–adrenal (HPA) axis. In the setting of stress, corticotrophin-releasing factor induces the release of adrenocorticotropic hormone, which stimulates the synthesis and secretion of glucocorticoids from the adrenal gland. Glucocorticoids exert a wide range of effects and can influence cardiovascular function, immunity and inflammation, metabolism, reproduction and fluid volume. An important target organ is the brain, where glucocorticoids can affect neuronal differentiation and excitability, behavioral reactivity, mood and cognition. This regulatory system works in conjunction with the sympatho-adrenal medullary system, which releases catecholamines, including noradrenaline and adrenaline. These systems are crucial for dealing with both physiological and psychological stress and restoring our steady state. Inappropriate regulation of the stress response has been linked to a wide array of pathologies, including hypertension, diabetes, osteoporosis and psychological disorders. In this chapter, we will focus on disorders of the HPA axis and their effects on mental health.

Keywords

HPA axisdepressionCushing’sAddison’smental health
Type
Chapter
Information
Mental Health, Diabetes and Endocrinology , pp. 43 - 55
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Charmandari, E, Tsigos, C, Chrousos, G. Endocrinology of the stress response. Annu Rev Physiol. 2005; 67: 259–84.Google Scholar
Smith, SM, Vale, WW. The role of the hypothalamic–pituitary–adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci. 2006; 8(4): 383–95.CrossRefGoogle ScholarPubMed
Sapolsky, RM, Romero, LM, Munck, AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000; 21(1): 55–89.Google ScholarPubMed
Koning, A-SCAM, Buurstede, JC, van Weert, LTCM, Meijer, OC. Glucocorticoid and mineralocorticoid receptors in the brain: a transcriptional perspective. J Endocr Soc. 2019; 3(10): 1917–30.CrossRefGoogle Scholar
Turner, AI, Smyth, N, Hall, SJ, Torres, SJ, Hussein, M, Jayasinghe, SU, et al. Psychological stress reactivity and future health and disease outcomes: a systematic review of prospective evidence. Psychoneuroendocrinology. 2020; 114: 104599.Google Scholar
Nieman, LK. Recent updates on the diagnosis and management of Cushing’s syndrome. Endocrinol Metab (Seoul). 2018; 33(2): 139–46.Google Scholar
Lacroix, A, Feelders, RA, Stratakis, CA, Nieman, LK, et al. Cushing’s syndrome. Lancet. 2015; 386(9996): 913–27.CrossRefGoogle ScholarPubMed
Starkman, MN, Schteingart, DE, Schork, MA. Depressed mood and other psychiatric manifestations of Cushing’s syndrome: relationship to hormone levels. Psychosom Med. 1981; 43(1): 3–18.CrossRefGoogle ScholarPubMed
Shipley, JE, Schteingart, DE, Tandon, R, Pande, AC, Grunhaus, L, Haskett, RF, Starkman, MN. EEG sleep in Cushing’s disease and Cushing’s syndrome: comparison with patients with major depressive disorder. Biol Psychiatry. 1992; 32(2): 146–55.Google Scholar
Starkman, MN, Schteingart, DE, Schork, MA. Correlation of bedside cognitive and neuropsychological tests in patients with Cushing’s syndrome. Psychosomatics. 1986; 27(7): 508–11.CrossRefGoogle ScholarPubMed
Haskett, RF. Diagnostic categorization of psychiatric disturbance in Cushing’s syndrome. Am J Psychiatry. 1985; 142(8): 911–6.Google Scholar
Santos, A, Resmini, E, Pascual, JC, Crespo, I, Webb, SM. Psychiatric symptoms in patients with Cushing’s syndrome: prevalence, diagnosis and management. Drugs. 2017; 77(8): 829–42.Google Scholar
Sonino, N, Zielezny, M, Fava, GA, Fallo, F, Boscaro, M. Risk factors and long-term outcome in pituitary-dependent Cushing’s disease. J Clin Endocrinol Metab. 1996; 81(7): 2647–52.Google Scholar
Starkman, MN. Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration. Endocrinol Metab Clin North Am. 2013; 42(3): 477–88.Google Scholar
Dorn, LD, Burgess, ES, Friedman, TC, Dubbert, B, Gold, PW, Chrousos, GP. The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab. 1997; 82(3): 912–9.Google Scholar
Sonino, N, Fava, GA, Belluardo, P, Girelli, ME, Boscaro, M. Course of depression in Cushing’s syndrome: response to treatment and comparison with Graves’ disease. Horm Res. 1993; 39(5–6): 202–6.CrossRefGoogle ScholarPubMed
Starkman, MN, Schteingart, DE, Schork, MA. Cushing’s syndrome after treatment: changes in cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Res. 1986; 19(3): 177–88.Google Scholar
Heald, AH, Ghosh, S, Bray, S, Gibson, C, Anderson, SG, Buckler, H, Fowler, HL. Long-term negative impact on quality of life in patients with successfully treated Cushing’s disease. Clin Endocrinol (Oxf). 2004; 61(4): 458–65.Google Scholar
Starkman, MN, Gebarski, SS, Berent, S, Schteingart, DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing’s syndrome. Biol Psychiatry. 1992; 32(9): 756–65.Google Scholar
Starkman, MN, Giordani, B, Gebarski, SS, Berent, S, Schork, MA, Schteingart, DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s disease. Biol Psychiatry. 1999; 46(12): 1595–602.Google Scholar
Bourdeau, I, Bard, C, Forget, H, Boulanger, Y, Cohen, H, Lacroix, A. Cognitive function and cerebral assessment in patients who have Cushing’s syndrome. Endocrinol Metab Clin North Am. 2005; 34(2): 357–69, ix.Google Scholar
Valassi, E, Crespo, I, Keevil, BG, Aulinas, A, Urgell, E, Santos, A, et al. Affective alterations in patients with Cushing’s syndrome in remission are associated with decreased BDNF and cortisone levels. Eur J Endocrinol. 2017; 176(2): 221–31.CrossRefGoogle ScholarPubMed
Lynch, S, Merson, S, Beshyah, SA, Skinner, E, Sharp, P, Priest, RG, Johnston, DG. Psychiatric morbidity in adults with hypopituitarism. J R Soc Med. 1994; 87(8): 445–7.Google Scholar
The 1950 Nobel Prize in Physiology or Medicine. Mayo Clin Proc. 2000; 75(12): 1232.CrossRefGoogle Scholar
Bénard-Laribière, A, Pariente, A, Pambrun, E, Bégaud, B, Fardet, L, Noize, P. Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France. BMJ Open. 2017; 7(7): e015905.CrossRefGoogle ScholarPubMed
Warrington, TP, Bostwick, JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006; 81(10): 1361–7.Google Scholar
Sirois, F. Steroid psychosis: a review. Gen Hosp Psychiatry. 2003; 25(1): 27–33.Google Scholar
Naber, D, Sand, P, Heigl, B. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment. A prospective study. Psychoneuroendocrinology. 1996; 21(1): 25–31.CrossRefGoogle ScholarPubMed
Brown, ES, Suppes, T, Khan, DA, Carmody 3rd, TJ. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol. 2002; 22(1): 55–61.Google Scholar
Bolanos, SH, Khan, DA, Hanczyc, M, Bauer, MS, Dhanani, N, Brown, ES. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol. 2004; 92(5): 500–5.Google Scholar
Wolkowitz, OM, Lupien, SJ. Bigler, ED. The ‘steroid dementia syndrome’: a possible model of human glucocorticoid neurotoxicity. Neurocase. 2007; 13(3): 189–200.CrossRefGoogle ScholarPubMed
Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther. 1972; 13(5): 694–8.Google Scholar
Stiefel, FC, Breitbart, WS, Holland, JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest. 1989; 7(5): 479–91.Google Scholar
Ling, MH, Perry, PJ, Tsuang, MT. Side effects of corticosteroid therapy. Psychiatric aspects. Arch Gen Psychiatry. 1981; 38(4): 471–7.Google Scholar
Brown, ES, Varghese, FP, McEwen, BS. Association of depression with medical illness: does cortisol play a role? Biol Psychiatry. 2004; 55(1): 1–9.CrossRefGoogle ScholarPubMed
Furst, DE, Saag, K. Glucocorticoid withdrawal, 2019. Available from: www.uptodate.com/contents/glucocorticoid-withdrawalGoogle Scholar
Hartgens, F, Kuipers, H. Effects of androgenic–anabolic steroids in athletes. Sports Med. 2004; 34(8): 513–54.Google Scholar
US Department of Justice Drug Enforcement Administration. A Guide for Understanding Steroids and Related Substances, 2004. Available from: www.deadiversion.usdoj.gov/pubs/brochures/steroids/professionalsGoogle Scholar
Maravelias, C, Dona, A, Stefanidou, M, Spiliopoulou, C. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol Lett. 2005; 158(3): 167–75.Google Scholar
Piacentino, D, Kotzalidis, GD, del Casale, A, Aromatario, MR, Pomara, C, Girardi, P, Sani, G. Anabolic–androgenic steroid use and psychopathology in athletes. A systematic review. Curr Neuropharmacol. 2015; 13(1): 101–21.Google Scholar
Pope, HG, Katz, DL. Psychiatric and medical effects of anabolic–androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. 1994; 51(5): 375–82.Google Scholar
Choi, PY, Pope, HG. Violence toward women and illicit androgenic–anabolic steroid use. Ann Clin Psychiatry. 1994; 6(1): 21–5.CrossRefGoogle ScholarPubMed
Perry, PJ, Kutscher, EC, Lund, BC, Yates, WR, Holman, TL, Demers, L. Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use. J Forensic Sci. 2003; 48(3): 646–51.Google Scholar
Lindqvist, AS, Moberg, T, Eriksson, BO, Ehrnborg, C, Rosén, T, Fahlke, C. A retrospective 30-year follow-up study of former Swedish-elite male athletes in power sports with a past anabolic androgenic steroids use: a focus on mental health. Br J Sports Med. 2013; 47(15): 965–9.CrossRefGoogle ScholarPubMed
Pärssinen, M, Kujala, U, Vartiainen, E, Sarna, S, Seppälä, T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med. 2000; 21(3): 225–7.CrossRefGoogle ScholarPubMed
Griffiths, S, Jacka, B, Degenhardt, L, Murray, SB, Larance, B. Physical appearance concerns are uniquely associated with the severity of steroid dependence and depression in anabolic–androgenic steroid users. Drug Alcohol Rev. 2018; 37(5): 664–70.CrossRefGoogle ScholarPubMed
Davis, C, Scott-Robertson, L. A psychological comparison of females with anorexia nervosa and competitive male bodybuilders: body shape ideals in the extreme. Eat Behav. 2000; 1(1): 33–46.CrossRefGoogle ScholarPubMed
Ip, EJ, Trinh, K, Tenerowicz, MJ, Pal, J, Lindfelt, TA, Perry, PJ. Characteristics and behaviors of older male anabolic steroid users. J Pharm Pract. 2015; 28(5): 450–6.CrossRefGoogle ScholarPubMed
Pope, HG, Katz, DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry. 1988; 145(4): 487–90.Google Scholar
Brower, KJ, Blow, FC, Beresford, TP, Fuelling, C. Anabolic–androgenic steroid dependence. J Clin Psychiatry. 1989; 50(1): 31–3.Google ScholarPubMed
Chabre, O, Goichot, B, Zenaty, D, Bertherat, J. Group 1. Epidemiology of primary and secondary adrenal insufficiency: prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality. Ann Endocrinol (Paris). 2017; 78(6): 490–4.CrossRefGoogle ScholarPubMed
Addison, T. On the Constitutional and Local Effects of Disease of the Suprarenal Capsules. Classics of Medicine Library, 1980.Google Scholar
Anglin, RE, Rosebush, PI, Mazurek, MF. The neuropsychiatric profile of Addison’s disease: revisiting a forgotten phenomenon. J Neuropsychiatry Clin Neurosci. 2006; 18(4): 450–9.Google Scholar
Shelton, RC. The molecular neurobiology of depression. Psychiatr Clin North Am. 2007; 30(1): 1–11.Google Scholar
Juruena, MF, Bocharova, M, Agustini, B, Young, AH. Atypical depression and non-atypical depression: Is HPA axis function a biomarker? A systematic review. J Affect Disord. 2018; 233: 45–67.Google Scholar
Belvederi Murri, M, Prestia, D, Mondelli, V, Pariante, C, Patti, S, Olivieri, B, et al. The HPA axis in bipolar disorder: systematic review and meta-analysis. Psychoneuroendocrinology. 2016; 63: 327–42.CrossRefGoogle ScholarPubMed
Carroll, BJ, Cassidy, F, Naftolowitz, D, Tatham, NE, Wilson, WH, Iranmanesh, A, et al. Pathophysiology of hypercortisolism in depression. Acta Psychiatr Scand Suppl. 2007; (433): 90–103.CrossRefGoogle Scholar
Belmaker, RH, Agam, G. Major depressive disorder. N Engl J Med. 2008; 358(1): 55–68.Google Scholar
Louis, C, Cohen, C, Depoortère, R, Griebel, G. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. Neuropsychopharmacology. 2006; 31(10): 2180–7.Google Scholar
Fadgyas-Stanculete, M, Buga, A-M, Popa-Wagner, A, Dumitrascu, DL. The relationship between irritable bowel syndrome and psychiatric disorders: from molecular changes to clinical manifestations. J Mol Psychiatry. 2014; 2(1): 4.Google Scholar
Farzi, A, Fröhlich, EE. Holzer, P. Gut microbiota and the neuroendocrine system. Neurotherapeutics. 2018; 15(1): 5–22.Google Scholar
Dinan, TG, Cryan, JF. The microbiome–gut–brain axis in health and disease. Gastroenterol Clin North Am. 2017; 46(1): 77–89.Google Scholar
Frank, MG, Thompson, BM, Watkins, LR, Maier, SF. Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses. Brain Behav Immun. 2012; 26(2): 337–45.Google Scholar
Westfall, S, Pasinetti, GM. The gut microbiota links dietary polyphenols with management of psychiatric mood disorders. Front Neurosci. 2019; 13: 1196.Google Scholar
Bancos, I, Schorr Haines, M, Wexler, J. Adrenal fatigue, 2020. Available from: www.hormone.org/diseases-and-conditions/adrenal-fatigueGoogle Scholar
Cadegiani, FA, Kater, CE. Adrenal fatigue does not exist: a systematic review. BMC Endocr Disord. 2016; 16(1): 48.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×